Last Updated : February 13, 2025
Details
Generic Name:
talazoparib
Project Status:
Pending
Therapeutic Area:
Metastatic castration-resistant prostate cancer
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Talzenna
Project Line:
Reimbursement Review
Project Number:
PC0417-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : February 13, 2025